

# Current State of Adjuvant Chemotherapy for Curatively Resected Colon Cancer at a Referral Center

Nobuharu YAMAMOTO, Koji MIKAMI, Yukiko ISHIBASHI,  
Yuji EGAWA, Daijiro HIGASHI, Kitaro FUTAMI, Takafumi MAEKAWA

*Department of Surgery, Chikushi Hospital, Fukuoka University.*

**Abstract: Background:** The guidelines for the treatment of colon cancer in Japan recommend adjuvant chemotherapy for the patients with stage III or stage II cancer, that are at high risk for recurrence. This study analyzed the adherence to adjuvant chemotherapy in this institute. **Patients and Methods:** All patients were proven to have stage II or III colon cancer; with D2 lymph-node dissection and no residual tumor (R0) in Fukuoka Chikushi Hospital and underwent adjuvant chemotherapy. **Results:** Sixty-one of the 114 patients who were recommended to receive adjuvant chemotherapy underwent the therapy. Many did not receive adjuvant chemotherapy due to their age. Thirty-two patients were treated with S-1, 18 UFT, 5 UFT/LV, 3 capecitabine and 3 S-1/CPT11. Treatment was continued for 6 months in 44 patients (72.1%). Treatment could not be continued due to an adverse event in 65% of the patients. Adverse events of grade 1 or 2 were in 10 patients and grade 3 was in only one. **Conclusion:** The patient's condition must be regularly checked by the doctors, pharmacists and nurses. The team needs to help patients to expand their knowledge of their disease and understanding to the treatment. Preventing adverse events will increase the patient's adherence.

**Key words :** Colon cancer, Adjuvant chemotherapy, Adherence, Team –oncology